A Multicenter, Randomized, Investigator- and Subject-Blind, Placebo-Controlled, Treatment Sequence Study Evaluating the Safety, Tolerability, and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis

Trial Profile

A Multicenter, Randomized, Investigator- and Subject-Blind, Placebo-Controlled, Treatment Sequence Study Evaluating the Safety, Tolerability, and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Aug 2018

At a glance

  • Drugs Rozanolixizumab (Primary)
  • Indications Myasthenia gravis
  • Focus Therapeutic Use
  • Sponsors UCB Biopharma
  • Most Recent Events

    • 11 Aug 2018 This trial was completed in Belgium (end date: 2018-08-06), according to European Clinical Trials Database.
    • 07 Aug 2018 This trial was completed in Denmark, according to European Clinical Trials Database.
    • 14 Jun 2018 This trial has been completed in Germany end date (2018-05-30).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top